tetano
Editor, Senior Moderator
Int J Infect Dis
. 2020 Aug 6;S1201-9712(20)30637-8.
doi: 10.1016/j.ijid.2020.08.012. Online ahead of print.
New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France
Timoth?e Klopfenstein[SUP] 1 [/SUP], Hajer Zahra[SUP] 2 [/SUP], N'dri Juliette Kadiane-Oussou[SUP] 3 [/SUP], Quentin Lepiller[SUP] 4 [/SUP], Pierre-Yves Royer[SUP] 3 [/SUP], Lynda Toko[SUP] 3 [/SUP], Vincent Gendrin[SUP] 3 [/SUP], Souheil Zayet[SUP] 5 [/SUP]
Affiliations
Abstract
Background: New loss of smell or taste was not included as common symptoms of COVID-19 until March 2020 when the pandemic started in Western countries. We want to describe the prevalence and features of anosmia and dysgeusia in COVID-19 patients.
Methods: We retrospectively investigated the clinical features of confirmed cases of COVID-19 in Nord Franche-Comt? Hospital, Trevenans, France, between March, 1st and March, 14th 2020. We used SARS-CoV-2 real time RT-PCR in respiratory samples to confirm the cases.
Results: Of 70 patient enrolled, the mean age was 57.0 years and 29 patients (41%) were men. Median Charlson comorbidity index was 1.70(?2.5). Twenty-seven (39%) patients had pneumonia. Fatigue (93% [65]), cough (80% [55]) and fever (77% [54]) were the three main symptoms. Neurologic symptoms were present in more than half of the patients: anosmia (53% [37]) and dysgeusia (48% [34]). The mean duration of anosmia was 7.4 (?5, [1-21]) days, 51% (36/70) recovered before 28 days of evolution. Only one patient with anosmia had not recovered at the end of the follow-up. Patients with anosmia had less often a pneumonia (10/37 vs 17/33, p = 0.036), were less often hospitalized (13/37 vs 20/33, p = 0.033) and needed less often oxygen therapy (6/37 vs 17/33, p = 0.002) than patients without anosmia. There were no statistically differences for viral load between patients with anosmia and patients without anosmia (5.5 [2.0-8.6] vs 5.3 [2.1-8.5] log copies/ml respectively, p = 0.670). The fatality of COVID-19 in our study was 6% with four deaths.
Conclusions: Anosmia and dysgeusia are present in half of COVID-19 patients. The mean duration of anosmia was 7 days and the outcome seems favorable in less than 28 days.
Keywords: Anosmia; Clinical features; Coronavirus disease 2019; Dysgeusia; Symptoms.
. 2020 Aug 6;S1201-9712(20)30637-8.
doi: 10.1016/j.ijid.2020.08.012. Online ahead of print.
New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France
Timoth?e Klopfenstein[SUP] 1 [/SUP], Hajer Zahra[SUP] 2 [/SUP], N'dri Juliette Kadiane-Oussou[SUP] 3 [/SUP], Quentin Lepiller[SUP] 4 [/SUP], Pierre-Yves Royer[SUP] 3 [/SUP], Lynda Toko[SUP] 3 [/SUP], Vincent Gendrin[SUP] 3 [/SUP], Souheil Zayet[SUP] 5 [/SUP]
Affiliations
- PMID: 32771635
- DOI: 10.1016/j.ijid.2020.08.012
Abstract
Background: New loss of smell or taste was not included as common symptoms of COVID-19 until March 2020 when the pandemic started in Western countries. We want to describe the prevalence and features of anosmia and dysgeusia in COVID-19 patients.
Methods: We retrospectively investigated the clinical features of confirmed cases of COVID-19 in Nord Franche-Comt? Hospital, Trevenans, France, between March, 1st and March, 14th 2020. We used SARS-CoV-2 real time RT-PCR in respiratory samples to confirm the cases.
Results: Of 70 patient enrolled, the mean age was 57.0 years and 29 patients (41%) were men. Median Charlson comorbidity index was 1.70(?2.5). Twenty-seven (39%) patients had pneumonia. Fatigue (93% [65]), cough (80% [55]) and fever (77% [54]) were the three main symptoms. Neurologic symptoms were present in more than half of the patients: anosmia (53% [37]) and dysgeusia (48% [34]). The mean duration of anosmia was 7.4 (?5, [1-21]) days, 51% (36/70) recovered before 28 days of evolution. Only one patient with anosmia had not recovered at the end of the follow-up. Patients with anosmia had less often a pneumonia (10/37 vs 17/33, p = 0.036), were less often hospitalized (13/37 vs 20/33, p = 0.033) and needed less often oxygen therapy (6/37 vs 17/33, p = 0.002) than patients without anosmia. There were no statistically differences for viral load between patients with anosmia and patients without anosmia (5.5 [2.0-8.6] vs 5.3 [2.1-8.5] log copies/ml respectively, p = 0.670). The fatality of COVID-19 in our study was 6% with four deaths.
Conclusions: Anosmia and dysgeusia are present in half of COVID-19 patients. The mean duration of anosmia was 7 days and the outcome seems favorable in less than 28 days.
Keywords: Anosmia; Clinical features; Coronavirus disease 2019; Dysgeusia; Symptoms.
